GammaCan International Reorganizes Board of Directors
16 November 2006 - 11:30PM
Business Wire
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of melanoma and other cancers,
today announced the reorganization of its Board of Directors. Mr.
Steven Katz and Mr. Albert Passner have joined the Board of
Directors of GammaCan International Inc. Mr. Katz has also been
named Chairman of the Board. At the same time, Dr. Lior
Soussan-Gutman and Mr. Jean-Pierre Elisha Martinez have left the
Board of GammaCan International Inc. and continue as Directors of
GammaCan Ltd., a subsidiary. �We are pleased to have Steven and
Albert join our Board. Steven brings extensive industry experience
to GammaCan. He is a successful entrepreneur, management consultant
and life sciences executive. GammaCan will be able to utilize
Steven�s industry background and experience as well as take
advantage of both Steven�s and Al�s experience as Directors of
public companies�, commented Patrick Schnegelsberg, GammaCan�s CEO.
Mr. Katz is currently the President of Steven Katz &
Associates, Inc., a health care and technology based management
consulting firm specializing in strategic planning, corporate
development, new product planning, technology licensing and
structuring and securing various forms of financing. Mr. Katz also
served as President, Chief Operating Officer and Director of
Senesco Technologies, Inc., an American Stock Exchange listed
company, engaged in the identification and development of
proprietary gene technology with application to human, animal and
plant systems. He co-founded and served as Executive Vice President
of S.K.Y. Polymers, Inc., a bio-materials company. Mr. Katz is
presently a member of the Board of Directors of the following
publicly-held corporations: Biophan Technologies, Inc., Nanoscience
Technologies, Inc., NaturalNano, Inc., and USA Technologies, Inc.
Mr. Passner has been an independent consultant since 2001. Prior to
that, he was a member of the technical staff of Lucent (AT&T)
Bell Laboratories for over 30 years. Mr. Passner is a member of the
Board of Directors of Nanoscience Technologies, Inc. and USA
Technologies, Inc. About GammaCan International Inc.: GammaCan is
focusing on the commercialization of an innovative anti-cancer
immunotherapy to treat metastatic cancer. GammaCan's platform is
based on IgG, a safe, relatively non-toxic human plasma-based
product, currently used to treat a variety of immune deficiencies
and autoimmune diseases. IgG works by strengthening the patient's
immune system. Many experts currently view immunotherapy as a
future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an
IgG derived from the plasma of vitiligo donors and is being
developed to treat malignant melanoma. GammaCan owns, and has
applied for US patent protection covering the use of IgG and
vitiligo-derived IgG (VitiGam). GammaCan International, Inc., owns
an 87 % interest in its Israeli subsidiary, GammaCan Ltd. About
VitiGam: VitiGam is GammaCan's second generation intravenous
IgG-based product and a first-in-class anti-cancer immunotherapy.
GammaCan plans on having VitiGam to enter phase I/II testing under
a US IND in the near future after it recently held a pre-IND
meeting with the FDA. VitiGam is being designed to target
metastatic melanoma patients with Stage III and IV melanoma.
VitiGam is an IgG product that is different from standard IgGs: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general For more
information about GammaCan visit www.GammaCan.com or call the
Company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar. GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of melanoma and other cancers,
today announced the reorganization of its Board of Directors. Mr.
Steven Katz and Mr. Albert Passner have joined the Board of
Directors of GammaCan International Inc. Mr. Katz has also been
named Chairman of the Board. At the same time, Dr. Lior
Soussan-Gutman and Mr. Jean-Pierre Elisha Martinez have left the
Board of GammaCan International Inc. and continue as Directors of
GammaCan Ltd., a subsidiary. "We are pleased to have Steven and
Albert join our Board. Steven brings extensive industry experience
to GammaCan. He is a successful entrepreneur, management consultant
and life sciences executive. GammaCan will be able to utilize
Steven's industry background and experience as well as take
advantage of both Steven's and Al's experience as Directors of
public companies", commented Patrick Schnegelsberg, GammaCan's CEO.
Mr. Katz is currently the President of Steven Katz &
Associates, Inc., a health care and technology based management
consulting firm specializing in strategic planning, corporate
development, new product planning, technology licensing and
structuring and securing various forms of financing. Mr. Katz also
served as President, Chief Operating Officer and Director of
Senesco Technologies, Inc., an American Stock Exchange listed
company, engaged in the identification and development of
proprietary gene technology with application to human, animal and
plant systems. He co-founded and served as Executive Vice President
of S.K.Y. Polymers, Inc., a bio-materials company. Mr. Katz is
presently a member of the Board of Directors of the following
publicly-held corporations: Biophan Technologies, Inc., Nanoscience
Technologies, Inc., NaturalNano, Inc., and USA Technologies, Inc.
Mr. Passner has been an independent consultant since 2001. Prior to
that, he was a member of the technical staff of Lucent (AT&T)
Bell Laboratories for over 30 years. Mr. Passner is a member of the
Board of Directors of Nanoscience Technologies, Inc. and USA
Technologies, Inc. About GammaCan International Inc.: GammaCan is
focusing on the commercialization of an innovative anti-cancer
immunotherapy to treat metastatic cancer. GammaCan's platform is
based on IgG, a safe, relatively non-toxic human plasma-based
product, currently used to treat a variety of immune deficiencies
and autoimmune diseases. IgG works by strengthening the patient's
immune system. Many experts currently view immunotherapy as a
future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an
IgG derived from the plasma of vitiligo donors and is being
developed to treat malignant melanoma. GammaCan owns, and has
applied for US patent protection covering the use of IgG and
vitiligo-derived IgG (VitiGam). GammaCan International, Inc., owns
an 87 % interest in its Israeli subsidiary, GammaCan Ltd. About
VitiGam: VitiGam is GammaCan's second generation intravenous
IgG-based product and a first-in-class anti-cancer immunotherapy.
GammaCan plans on having VitiGam to enter phase I/II testing under
a US IND in the near future after it recently held a pre-IND
meeting with the FDA. VitiGam is being designed to target
metastatic melanoma patients with Stage III and IV melanoma.
VitiGam is an IgG product that is different from standard IgGs: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general For more
information about GammaCan visit www.GammaCan.com or call the
Company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024